CVE:TLT

Theralase Technologies Stock Forecast, Price & News

C$0.20
-0.01 (-2.38 %)
(As of 09/17/2021 12:16 PM ET)
Add
Compare
Today's Range
C$0.21
C$0.21
50-Day Range
C$0.21
C$0.28
52-Week Range
C$0.12
C$0.32
Volume87,005 shs
Average Volume245,447 shs
Market CapitalizationC$41.88 million
P/E RatioN/A
Dividend Yield2.03%
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive TLT News and Ratings via Email

Sign-up to receive the latest news and ratings for Theralase Technologies and its competitors with MarketBeat's FREE daily newsletter.


About Theralase Technologies

Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of photo dynamic compounds (PDCs) and their associated drug formulations to treat cancer in Canada, the United States, and internationally. The company also designs, develops, manufactures, and commercializes medical laser systems and other technologies for the activation of PDCs; designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. The company is developing TLD-1433, which is in Phase II for the treatment of non-muscle invasive bladder cancer (NMIBC). Its products include TLC-1000, TLC-2000, and controllerless series laser technology products for the elimination of pain, reduction of inflammation, and acceleration of tissue healing, as well as TLC-1000 and TLC-2000 accessories; and Theralase therapeutic laser treatments for patients, including pain management, arthritis, wound healing, addiction rehabilitation and weight loss, and anti-aging, as well as companion animals and equine. Theralase Technologies Inc. has research agreements with the University of Manitoba Medical Microbiology department for the development of a coronavirus vaccine and therapy; and the National Microbiolog Laboratory and Public Health Agency of Canada for the research and development of a Canadian-based SARS-CoV-2 vaccine. The company sells its products to healthcare practitioners. Theralase Technologies Inc. was founded in 1994 and is headquartered in Toronto, Canada.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.43 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.7Dividend Strength: 0.8Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Theralase Technologies (CVE:TLT) Frequently Asked Questions

What stocks does MarketBeat like better than Theralase Technologies?

Wall Street analysts have given Theralase Technologies a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Theralase Technologies wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Theralase Technologies' next earnings date?

Theralase Technologies is scheduled to release its next quarterly earnings announcement on Friday, November 26th 2021.
View our earnings forecast for Theralase Technologies
.

How has Theralase Technologies' stock been impacted by Coronavirus (COVID-19)?

Theralase Technologies' stock was trading at C$0.25 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, TLT stock has decreased by 18.0% and is now trading at C$0.21.
View which stocks have been most impacted by COVID-19
.

Is Theralase Technologies a good dividend stock?

Theralase Technologies pays an annual dividend of C$2.90 per share and currently has a dividend yield of 2.03%.
View Theralase Technologies' dividend history.

Who are Theralase Technologies' key executives?

Theralase Technologies' management team includes the following people:
  • Dr. Shawn Shirazi B.Sc., M.Sc., Ph.D., Chief Exec. Officer
  • Ms. Kristina Hachey CPA, CFO & Director
  • Dr. Arkady Mandel, Chief Scientific Officer & Director
  • Mr. David M. Groves B.A, Pres of World Trade Division
  • Mr. Roger John Dumoulin-White, Director of Bus. Devel.
  • Lori Leach, Marketing & Media Relations Consultant
  • Mr. Vaughn Wyant, Marketing & Media Relations Consultant
  • Dr. Terry Ruch DVM, Equine Medical Consultant

Who are some of Theralase Technologies' key competitors?

What other stocks do shareholders of Theralase Technologies own?

What is Theralase Technologies' stock symbol?

Theralase Technologies trades on the Canadian Venture Exchange (CVE) under the ticker symbol "TLT."

How do I buy shares of Theralase Technologies?

Shares of TLT and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Theralase Technologies' stock price today?

One share of TLT stock can currently be purchased for approximately C$0.21.

How much money does Theralase Technologies make?

Theralase Technologies has a market capitalization of C$41.88 million and generates C$1.07 million in revenue each year.

How many employees does Theralase Technologies have?

Theralase Technologies employs 20 workers across the globe.

What is Theralase Technologies' official website?

The official website for Theralase Technologies is theralase.com.

Where are Theralase Technologies' headquarters?

Theralase Technologies is headquartered at 1945 Queen St E, TORONTO, ON M4L 1H7, Canada.

How can I contact Theralase Technologies?

Theralase Technologies' mailing address is 1945 Queen St E, TORONTO, ON M4L 1H7, Canada. The company can be reached via phone at +1-416-6995273.


This page was last updated on 9/19/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.